+44 (0) 1223 755950
+1 832 327 7413
Mavrilimumab
REQUEST MORE INFO
Catalogue No: abx831195
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Mavrilimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CSF2RA/CD116, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
Research Articles on CSF2RA/CD116
| Target | CSF2RA/CD116 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG4 Lambda2 |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1085337-57-0 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |